Japanese research team found substances that promote cancer metastasis June 20, 2018 Source: World Wide Web According to a report by the Kyodo News Agency on June 20, a research team of the Japanese Shiga Medical University professor Fan Tianjiu (Molecular Pathology Biochemistry) released a message on the 19th that a protein called "EMP1" has been discovered to promote cancer metastasis. Researchers believe that if the amount of EMP1 can be grasped, it will become a marker of whether cancer is easy to metastasize. If substances that inhibit its activity are found, it is possible to develop new agents that prevent cancer from spreading or spreading around. The results have been published in the electronic version of the international professional magazine. The team analyzed the genes that play a role in cancer cells in the early stages of metastasis, and found that genes that produce EMP1 are active on the cell surface. The researchers produced prostate cancer cells that produced large amounts of EMP1. After transplanting the cancer cells into the prostate of the experimental mice, the cancer metastasized to the lymph and lungs. In contrast, no metastasis was found in the transplantation of prostate cancer cells that did not substantially produce EMP1. This leads to the conclusion that EMP1 is closely related to metastasis. In addition, the researchers also found that EMP1 on the surface of cancer cells binds to other proteins in cancer cells, improves cell metastasis, and promotes cancer metastasis. Fan Tian believes that the deaths caused by cancer are mostly caused by metastasis, indicating that "it is hoped to reduce the death caused by cancer by inhibiting metastasis." (Global Network Reporter Wang Huan)
Antimalarial:
Antimalarial
medications, also known as antimalarials, are designed to prevent or cure
malaria. Such drugs may be used for some or all of the following:
Treatment of
malaria in individuals with suspected or confirmed infection
Prevention of
infection in individuals visiting a malaria-endemic region who have no immunity
(Malaria prophylaxis)
Routine
intermittent treatment of certain groups in endemic regions (Intermittent
preventive therapy)
Some antimalarial
agents, particularly chloroquine and hydroxychloroquine, are also used in the
treatment of rheumatoid arthritis and lupus-associated arthritis.
Current practice
in treating cases of malaria is based on the concept of combination therapy,
since this offers several advantages, including reduced risk of treatment
failure, reduced risk of developing resistance, enhanced convenience, and
reduced side-effects. Prompt parasitological confirmation by microscopy, or
alternatively by rapid diagnostic tests, is recommended in all patients
suspected of malaria before treatment is started. Treatment solely on the basis
of clinical suspicion should only be considered when a parasitological
diagnosis is not accessible.
Antiparasitic:
Antiparasitics are
a class of medications which are indicated for the treatment of parasitic
diseases, such as those caused by helminths,amoeba, ectoparasites, parasitic
fungi, and protozoa, among others. Antiparasitics target the parasitic agents
of the infections by destroying them or inhibiting their growth;[4] they are
usually effective against a limited number of parasites within a particular
class. Antiparasitics are one of the antimicrobial drugs which include
antibiotics that target bacteria, and antifungals that target fungi. They may
be administered orally, intravenously or topically.
Broad-spectrum
antiparasitics, analogous to broad-spectrum antibiotics for bacteria, are
antiparasitic drugs with efficacy in treating a wide range of parasitic infections
caused by parasites from different classes.
Antimalarial & Antiparasitic,Antimalarial Drugs,Artemether Lumefantrine,Antiparasitic Drugs,Mebendazole Tablets NOUVASANT GROUP LTD. , https://www.nouvasant.com
Japanese research team found substances that promote cancer metastasis
Prev Article
Rapeseed "flower but not real", why?